| [1] |
1 Huether A, Hopfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer[J]. Biochem Pharmacol, 2005, 70(11):1568~1578
2 Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck [J]. Cancer Res, 1999, 59(8):1935~1940
3 Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human- murine monoclonal antibody [J]. Drugs Today (Barc), 2005, 41(2):107~127
4 Sung FL, Poon TC, Hui EP, et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells [J]. In Vivo, 2005, 19(1):237~245
5 Rose WC, Wild R. Therapeutic synergy of oral taxane BMS275183 and cetuximab versus human tumor xenografts [J]. Clin Cancer Res, 2004, 10(21):7413~7417
6 Milas L, Fan Z, Andratschke NH, et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies [J]. Int JRadiat Oncol Biol Phys, 2004, 58(3):966~971
7 Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5- fluorouracil/folinic acid is a safe combination for the firstline treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma [J]. Ann Oncol, 2006, 17(3):450~456
8 Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan - refractory metastatic colorectal cancer [J]. N Engl JMed, 2004, 351(4): 337~345
9 Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J]. J Clin Oncol, 2005, 23(9):1803~1810
10 Shin DM, Donato NJ, Perez- Soler R, et al. Epidermal growth factor receptor- targeted therapy with C225 and cisplatin in patients with head and neck cancer [J]. Clin Cancer Res, 2001, 7(5): 1204~1213
11 Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma [J]. J Clin Oncol, 2005, 23(15):3568~3576
12 Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study [J]. J Clin Oncol, 2005, 23 (34):8646~8654
13 Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck [J]. N Engl JMed, 2006, 354(6):567~578
14 Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first- line treatment of patients (pts) with epidermal growth factor receptor (EGFR)- expressing advanced non- small cell lung cancer (NSCLC)[J]. Proc Am Soc Clin Oncol, 2004, 23:618
15 Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy- naive advanced non- small- cell lung cancer [J]. J Clin Oncol, 2005, 23(36):9089~9096
16 Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non- small- cell lung cancer [J]. J Clin Oncol, 2005, 23(34):8786~8793
17 Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial [J]. JClin Oncol, 2004, 22 (13):2610~2616
18 Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma [J]. Invest New Drugs, 2003, 21 (1): 99101
19 Wu G, Barth RF, Yang W,et al. Site- specific conjugation of boron- containing dendrimers to anti- EGF receptor monoclonal antibody cetuximab (IMC- C225) and its evaluation as a potential delivery agent for neutron capture therapy [J]. Bioconjug Chem, 2004, 15(1):185~194
20 Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab mimotopes and biological properties of induced anti- epidermal growth factor receptor antibodies [J]. J Natl Cancer Inst, 2005, 97(22):1663~1670
|
下载:
